Data / Drug companies / A2A Integrated Pharmaceuticals
A2A Integrated Pharmaceuticals: 12 products in the FDA NDC directory, labeler code 73141
A2A Integrated Pharmaceuticals (labeler code 73141) lists 12 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 10 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 8, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73141
- Products in commercial distribution
- 12
- Packages
- 14
- Finished drugs by generic name
- 9
- Prescription products
- 10
- Over the counter products
- 2
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- March 15, 2024
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 10 | 83.3% |
| Over the counter monograph drugs | 2 | 16.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 10 | 83.3% |
| Over the counter drugs | 2 | 16.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Maraviroc | 2 | 9 |
| Gaunfacine | 2 | 3 |
| Ranolazine | 2 | 30 |
| Chlorhexidine gluconate, 0.12% oral rinse | 1 | 3 |
| Isosorbide dinitrate and hydralazine hydrochloride | 1 | 3 |
| Selegiline hydrochloride | 1 | 12 |
| Posaconazole | 1 | 29 |
| Capsaicin | 1 | 66 |
| Hydrocortisone | 1 | 171 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 3 | 25% |
| Tablet | 3 | 25% |
| Cream | 2 | 16.7% |
| Tablet, film coated, extended release | 2 | 16.7% |
| Solution | 1 | 8.3% |
| Tablet, delayed release | 1 | 8.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ranolazine | 73141-022 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 8, 2025 |
| Ranolazine | 73141-021 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 8, 2025 |
| Guanfacine | 73141-019 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Guanfacine | 73141-018 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Hydrocortisone | 73141-622 | Cream | Over the counter monograph drugs | March 28, 2025 |
| Chlorhexidine Gluconate, 0.12% Oral Rinse Solution | 73141-512 | Solution | Generic drugs (ANDA) | December 10, 2024 |
| Maraviroc | 73141-025 | Tablet, film coated | Generic drugs (ANDA) | May 16, 2024 |
| Maraviroc | 73141-024 | Tablet, film coated | Generic drugs (ANDA) | May 16, 2024 |
| Posaconazole | 73141-023 | Tablet, delayed release | Generic drugs (ANDA) | May 16, 2024 |
| Isosorbide dinitrate and hydralazine hydrochloride | 73141-012 | Tablet, film coated | Generic drugs (ANDA) | April 22, 2024 |
| Capsaicin Cream | 73141-558 | Cream | Over the counter monograph drugs | March 25, 2024 |
| Selegiline Hydrochloride | 73141-006 | Tablet | Generic drugs (ANDA) | March 15, 2024 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.